EDR Tripeptide · Pineal Bioregulator · Glu-Asp-Arg
A short tripeptide bioregulator (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation and Gerontology specifically targeting the pineal gland. Pinealon restores melatonin synthesis, regulates circadian rhythm, provides neuroprotection and demonstrates significant anti-aging effects — with over 30 years of Russian clinical research behind it.
Pinealon is a short tripeptide bioregulator consisting of three amino acids — glutamic acid, aspartic acid and arginine (EDR). Developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, it was designed to specifically regulate pineal gland function. The pineal gland is responsible for melatonin synthesis, circadian rhythm regulation and plays a central role in neuroendocrine function. Pinealon works by penetrating cell nuclei and directly interacting with DNA to restore normal gene expression in pineal cells that have been suppressed by aging or stress.
Unlike synthetic melatonin supplementation which simply replaces the hormone, Pinealon works upstream — restoring the pineal gland's own capacity to produce melatonin naturally. It achieves this through epigenetic regulation: the EDR tripeptide enters pinealocyte nuclei and interacts with gene promoter regions, reactivating genes responsible for melatonin synthesis that become silenced with age. This results in restored natural melatonin rhythms rather than blunt exogenous supplementation. Additionally Pinealon demonstrates direct neuroprotective effects through antioxidant activity and modulation of serotonin metabolism.
One of the most consistently reported benefits in both clinical research and user experience is dramatic improvement in sleep quality. Pinealon restores the natural nocturnal melatonin surge that diminishes with age, stress and modern light exposure. Unlike standard melatonin supplementation, the effect is physiological — the gland secretes melatonin in its natural pulsatile pattern rather than a flat exogenous dose. This translates to improved sleep onset, deeper slow-wave sleep and more restorative sleep architecture. Particularly relevant for individuals with delayed sleep phase, shift work patterns or high stress loads.
Beyond sleep, Pinealon demonstrates significant neuroprotective properties. Published research shows it reduces oxidative stress in neural tissue, modulates serotonin-melatonin pathways, and demonstrates protective effects against neurodegenerative processes. In animal studies it improved cognitive performance in aged subjects and showed protective effects in models of ischemia. The serotonergic modulation also contributes to mood stabilisation — consistent with the pineal gland's broader role in emotional regulation.
The St. Petersburg group has published long-term data on peptide bioregulators including Pinealon showing significant mortality reduction in human cohorts. The pineal gland is considered a master regulator of aging in neuroendocrine theory — its progressive calcification and melatonin decline are directly correlated with the aging phenotype. By restoring pineal function, Pinealon addresses aging at a regulatory rather than symptomatic level. It is frequently combined with Epithalon (another St. Petersburg bioregulator targeting telomerase) for comprehensive anti-aging protocols.
Pinealon is typically run as a 10-day course, 1–2 times per year. Standard dose is 1mg per day administered SubQ or orally in the evening before bed — timing aligned with the natural melatonin secretion window. SubQ provides more reliable absorption. The 10-day course format mirrors the original Russian clinical protocols and is the most evidence-backed approach.